Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: getinfo@lktlabs.com
Web: lktlabs.com

## **Product Information**

Product ID G7342

CAS No. 1086062-66-9

Chemical Name 2,4-difluoro-N-[2-methoxy-5-(4-pyridazin-4-ylquinolin-6-yl)pyridin-3-

yl] benzenesulfonamide

Synonym GSK458, Omipalisib

 $\textbf{Formula} \quad C_{25}H_{17}F_2N_5O_3S$ 

Formula Wt. 505.50

**Melting Point** 

Purity ≥99%

Solubility DMSO 100 mg/mL (197.82 mM)

Water Insoluble Ethanol Insoluble

Store Temp -20°C Ship Temp Ambient

 $\textbf{Description} \quad \text{GSK-}2126458 \text{ is an ATP-competitive PI3K and mTOR inhibitor somewhat specific for the } p110\alpha \text{ isoform of PI3K. This compound}$ 

 $exhibits\ anticancer\ chemother apeutic\ activity,\ inhibiting\ growth\ in\ cellular\ models.\ GSK-2126458\ is\ currently\ in\ clinical\ trials$ 

for treatment of a variety of solid tumor cancers.

## P F N

## **Pricing and Availability**

## Bulk quanitites available upon request

Product ID	Size	List Price
G7342	1 mg	\$52.20
G7342	5 mg	\$98.50
G7342	25 mg	\$301.00

References Greger JG, Eastman SD, Zhang V, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther. 2012 Apr;11(4):909-20. PMID: 22389471.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.